Last reviewed · How we verify

Kyowa Kirin — Portfolio Competitive Intelligence Brief

Kyowa Kirin (4151.T) pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4151.T (TSE) 4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Nourianz ISTRADEFYLLINE marketed CYP3A4 Substrates Adenosine receptor A2a Neuroscience 2019-01-01
Poteligeo MOGAMULIZUMAB marketed Chemokine Receptor Type 4 Interaction [EPC] C-C chemokine receptor type 4 Oncology 2018-01-01
Fareston TOREMIFENE marketed Estrogen Agonist/Antagonist 5-hydroxytryptamine receptor 6 Oncology 1997-01-01
CRYSVITA BUROSUMAB-TWZA marketed Fibroblast growth factor 23 Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eli Lilly · 1 shared drug class
  2. H. Lee Moffitt Cancer Center and Research Institute · 1 shared drug class
  3. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kyowa Kirin:

Cite this brief

Drug Landscape (2026). Kyowa Kirin — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kyowa-kirin. Accessed 2026-05-16.

Related